ImmuCell Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for ImmuCell.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 27.6% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
No updates
Recent updates
ImmuCell Corporation (NASDAQ:ICCC) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
Dec 04ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt
Nov 30Revenues Working Against ImmuCell Corporation's (NASDAQ:ICCC) Share Price
Aug 07ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt
Aug 10Insufficient Growth At ImmuCell Corporation (NASDAQ:ICCC) Hampers Share Price
May 27ImmuCell GAAP EPS of -$0.09, revenue of $3.86M
Aug 11ImmuCell announces preliminary 2Q sales of $3.9M
Jul 07Health Check: How Prudently Does ImmuCell (NASDAQ:ICCC) Use Debt?
Sep 15Why We Think Shareholders May Be Considering Bumping Up ImmuCell Corporation's (NASDAQ:ICCC) CEO Compensation
Jun 10Is ImmuCell (NASDAQ:ICCC) Using Too Much Debt?
Mar 15Does ImmuCell's (NASDAQ:ICCC) Share Price Gain of 38% Match Its Business Performance?
Jan 22ImmuCell reports FY20 preliminary sales
Jan 07ImmuCell restructures its bank debt
Dec 15ImmuCell EPS beats by $0.04, beats on revenue
Nov 12In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ImmuCell has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
9/30/2024 | 24 | -4 | -1 | 0 | N/A |
6/30/2024 | 23 | -4 | -1 | 0 | N/A |
3/31/2024 | 21 | -4 | -3 | -1 | N/A |
12/31/2023 | 17 | -6 | -7 | -5 | N/A |
9/30/2023 | 16 | -6 | -9 | -5 | N/A |
6/30/2023 | 16 | -6 | -10 | -6 | N/A |
3/31/2023 | 16 | -5 | -9 | -5 | N/A |
12/31/2022 | 19 | -2 | -6 | -2 | N/A |
9/30/2022 | 20 | -1 | -3 | 0 | N/A |
6/30/2022 | 20 | 0 | -1 | 2 | N/A |
3/31/2022 | 21 | 1 | -1 | 2 | N/A |
12/31/2021 | 19 | 0 | -2 | 1 | N/A |
9/30/2021 | 18 | 0 | -2 | 1 | N/A |
6/30/2021 | 16 | 0 | -3 | 0 | N/A |
3/31/2021 | 15 | -1 | -3 | 0 | N/A |
12/31/2020 | 15 | -1 | -3 | 1 | N/A |
9/30/2020 | 15 | -2 | -3 | 1 | N/A |
6/30/2020 | 14 | -2 | -2 | 2 | N/A |
3/31/2020 | 14 | -2 | -2 | 0 | N/A |
12/31/2019 | 14 | -1 | -1 | 0 | N/A |
9/30/2019 | 13 | -2 | -1 | 0 | N/A |
6/30/2019 | 12 | -2 | -1 | 0 | N/A |
3/31/2019 | 13 | -2 | -1 | 0 | N/A |
12/31/2018 | 11 | -2 | -2 | 0 | N/A |
9/30/2018 | 11 | -1 | -7 | 0 | N/A |
6/30/2018 | 11 | -2 | N/A | 0 | N/A |
3/31/2018 | 10 | -1 | N/A | 0 | N/A |
12/31/2017 | 10 | 0 | N/A | 1 | N/A |
9/30/2017 | 10 | 0 | N/A | 0 | N/A |
6/30/2017 | 9 | 0 | N/A | 1 | N/A |
3/31/2017 | 10 | 1 | N/A | 1 | N/A |
12/31/2016 | 10 | 1 | N/A | 0 | N/A |
9/30/2016 | 10 | 1 | N/A | 1 | N/A |
6/30/2016 | 11 | 1 | N/A | 2 | N/A |
3/31/2016 | 10 | 1 | N/A | 1 | N/A |
12/31/2015 | 10 | 1 | N/A | 3 | N/A |
9/30/2015 | 10 | 1 | N/A | 2 | N/A |
6/30/2015 | 9 | 1 | N/A | 1 | N/A |
3/31/2015 | 9 | 0 | N/A | 1 | N/A |
12/31/2014 | 8 | 0 | N/A | 0 | N/A |
9/30/2014 | 7 | 0 | N/A | 0 | N/A |
6/30/2014 | 6 | 0 | N/A | 0 | N/A |
3/31/2014 | 6 | 0 | N/A | 1 | N/A |
12/31/2013 | 6 | 0 | N/A | 1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if ICCC's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if ICCC's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if ICCC's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if ICCC's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if ICCC's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ICCC's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/24 22:16 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ImmuCell Corporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Nathan Weinstein | Aegis Capital Corporation |